Your browser is no longer supported. Please, upgrade your browser.
Settings
TCDA [NASD]
Tricida, Inc.
Index- P/E- EPS (ttm)-5.37 Insider Own1.50% Shs Outstand50.12M Perf Week-32.87%
Market Cap346.99M Forward P/E- EPS next Y-3.26 Insider Trans-7.75% Shs Float48.88M Perf Month-30.74%
Income-268.10M PEG- EPS next Q-1.02 Inst Own92.00% Short Float10.36% Perf Quarter-36.17%
Sales- P/S- EPS this Y-43.00% Inst Trans0.29% Short Ratio5.98 Perf Half Y-53.80%
Book/sh3.21 P/B1.50 EPS next Y26.50% ROA-60.60% Target Price- Perf Year-84.90%
Cash/sh4.40 P/C1.09 EPS next 5Y- ROE-109.90% 52W Range3.74 - 35.16 Perf YTD-31.91%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-86.35% Beta-
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low28.34% ATR0.61
Employees195 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)29.01 Volatility10.96% 6.85%
OptionableYes Debt/Eq1.20 EPS Q/Q-73.60% Profit Margin- Rel Volume2.89 Prev Close5.11
ShortableYes LT Debt/Eq1.11 EarningsFeb 25 AMC Payout- Avg Volume847.18K Price4.80
Recom2.70 SMA20-30.80% SMA50-33.05% SMA200-63.34% Volume2,444,963 Change-6.07%
Sep-29-20Resumed JP Morgan Underweight $8
Aug-25-20Downgrade Goldman Buy → Neutral $25 → $10
Jun-27-19Initiated Goldman Buy $48
May-24-19Initiated Needham Buy $50
Jul-23-18Initiated JP Morgan Neutral $34
Jul-23-18Initiated Goldman Neutral $32
Mar-01-21 08:46PM  
07:16PM  
04:07PM  
03:25PM  
02:09PM  
12:40PM  
11:15AM  
11:07AM  
11:00AM  
10:00AM  
10:00AM  
09:32AM  
09:29AM  
Feb-28-21 10:30AM  
09:01AM  
Feb-27-21 06:00PM  
08:27AM  
Feb-26-21 02:00PM  
12:20PM  
11:20AM  
08:16AM  
06:22AM  
Feb-25-21 09:09PM  
07:38PM  
06:45PM  
05:34PM  
04:40PM  
04:10PM  
04:05PM  
02:30PM  
01:00PM  
12:30PM  
12:30PM  
11:15AM  
10:15AM  
Feb-24-21 05:30PM  
05:00PM  
04:58PM  
02:30PM  
01:55PM  
12:15PM  
12:00PM  
11:30AM  
Feb-23-21 08:11PM  
07:00PM  
03:10PM  
02:36PM  
11:27AM  
11:25AM  
10:00AM  
Feb-22-21 09:20PM  
02:36PM  
12:15PM  
11:50AM  
11:15AM  
11:00AM  
10:06AM  
09:00AM  
08:15AM  
Feb-21-21 02:00PM  
Feb-20-21 05:45PM  
07:45AM  
Feb-19-21 07:40PM  
01:03PM  
11:25AM  
12:25AM  
Feb-18-21 11:55PM  
08:15PM  
01:45PM  
12:15PM  
11:30AM  
10:30AM  
09:21AM  
Feb-17-21 08:35PM  
08:10PM  
06:05PM  
06:00PM  
05:14PM  
05:00PM  
04:00PM  
12:00PM  
11:30AM  
Feb-16-21 05:45PM  
04:32PM  
01:58PM  
12:30PM  
12:30PM  
11:30AM  
11:00AM  
Feb-15-21 09:14PM  
07:40PM  
12:45PM  
12:45PM  
12:18PM  
Feb-14-21 10:30AM  
Feb-13-21 04:50PM  
01:10PM  
Feb-12-21 12:45PM  
12:00PM  
Feb-11-21 06:53PM  
Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COUFAL SANDRA IDirectorFeb 24Sale8.01100801162,509Feb 26 04:41 PM
KLAERNER GERRITPresident and CEOFeb 08Sale7.268,00058,080499,993Feb 09 05:39 PM
COUFAL SANDRA IDirectorFeb 03Sale6.915,00034,550162,609Feb 04 06:00 PM
COUFAL SANDRA IDirectorJan 26Sale7.065,00035,300167,609Jan 27 05:39 PM
KLAERNER GERRITPresident and CEOJan 14Sale7.181,65511,883507,993Jan 15 04:32 PM
KLAERNER GERRITPresident and CEOJan 13Sale7.4115,035111,409509,648Jan 15 04:32 PM
KLAERNER GERRITPresident and CEOJan 12Sale7.659,82175,131524,683Jan 13 04:38 PM
KLAERNER GERRITPresident and CEOJan 11Sale7.4921,489160,953534,504Jan 12 04:31 PM
COUFAL SANDRA IDirectorDec 14Sale7.9050,000395,000172,609Dec 15 05:46 PM
McKague RobertEVP, General CounselDec 11Buy7.6210,00076,20010,000Dec 23 05:34 PM
Parker Geoffrey M.CFO and EVPDec 10Buy6.7815,000101,70040,000Dec 10 07:46 PM
KLAERNER GERRITPresident and CEOJul 15Sale26.334,000105,32025,323Jul 16 07:30 PM
KLAERNER GERRITPresident and CEOJul 01Sale27.154,000108,600547,321Jul 02 04:57 PM
KLAERNER GERRITPresident and CEOJun 15Sale25.974,000103,86929,323Jun 16 08:14 PM
KLAERNER GERRITPresident and CEOJun 01Sale26.234,000104,920551,321Jun 03 04:39 PM
KLAERNER GERRITPresident and CEOMay 15Sale31.564,000126,22033,323May 19 07:07 PM
Parker Geoffrey M.Chief Fin. Officer and EVPMay 12Buy30.912,74284,76695,000May 12 08:45 PM
Parker Geoffrey M.Chief Fin. Officer and EVPMay 11Buy30.0232,258968,43792,258May 12 08:45 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMay 08Option Exercise3.033,0009,0991,692May 12 08:38 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMay 08Sale31.983,00095,940255May 12 08:38 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMay 05Option Exercise1.941,2502,4211,053May 07 05:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMay 05Sale30.141,25037,680255May 07 05:33 PM
KLAERNER GERRITPresident and CEOMay 01Sale27.984,000111,906555,321May 04 05:34 PM
Otto Dawn ParsellEVP, Clinical DevelopmentApr 29Option Exercise2.823,0008,4501,999Apr 30 04:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentApr 29Sale31.983,00095,940255Apr 30 04:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentApr 28Option Exercise1.681,2502,1001,505Apr 30 04:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentApr 28Sale29.981,25037,475255Apr 30 04:33 PM
KLAERNER GERRITPresident and CEOApr 15Sale27.474,000109,89137,323Apr 16 08:05 PM
KLAERNER GERRITPresident and CEOApr 06Sale24.224,00096,880559,321Apr 08 04:34 PM
KLAERNER GERRITPresident and CEOMar 16Sale23.914,00095,64041,323Mar 18 04:09 PM
Parker Geoffrey M.Chief Fin. Officer and EVPMar 10Buy29.465,000147,30055,000Mar 11 05:10 PM
HEJLEK EDWARD JEVP, General Counsel & Secy.Mar 02Option Exercise0.9610,0009,60028,953Mar 04 07:36 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMar 02Option Exercise2.484,25010,5503,249Mar 04 07:38 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMar 02Sale31.844,250135,316255Mar 04 07:38 PM
HEJLEK EDWARD JEVP, General Counsel & Secy.Mar 02Sale31.6610,000316,61619,153Mar 04 07:36 PM
KLAERNER GERRITPresident and CEOMar 02Sale31.534,000126,120563,321Mar 04 07:33 PM